GW&K Investment Management LLC reduced its stake in Vericel Corporation (NASDAQ:VCEL – Free Report) by 0.8% during the third quarter, according to its most recent filing with the SEC. The fund owned 1,538,006 shares of the biotechnology company’s stock after selling 12,491 shares during the quarter. GW&K Investment Management LLC’s holdings in Vericel were worth $61,736,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. MCF Advisors LLC grew its position in Vericel by 293.0% during the second quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 583 shares during the period. Ameritas Advisory Services LLC purchased a new stake in Vericel during the second quarter worth about $36,000. Hantz Financial Services Inc. raised its position in Vericel by 24.8% in the third quarter. Hantz Financial Services Inc. now owns 1,194 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 237 shares during the period. Allworth Financial LP bought a new stake in Vericel in the second quarter worth about $60,000. Finally, Integrated Wealth Concepts LLC bought a new stake in Vericel in the second quarter worth about $72,000.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on VCEL shares. TD Cowen boosted their target price on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th. BTIG Research restated a “neutral” rating on shares of Vericel in a research note on Wednesday. Wall Street Zen raised shares of Vericel from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. Finally, Stephens upped their price objective on Vericel from $55.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, November 10th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Vericel has a consensus rating of “Moderate Buy” and an average target price of $62.00.
Get Our Latest Stock Analysis on Vericel
Vericel Stock Down 0.7%
VCEL stock opened at $58.26 on Friday. The firm has a market capitalization of $2.97 billion, a PE ratio of 91.03 and a beta of 1.08. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $59.75. The stock has a 50-day simple moving average of $44.31 and a two-hundred day simple moving average of $39.84.
Vericel (NASDAQ:VCEL – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.21. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The firm had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. During the same period in the prior year, the firm posted $0.10 earnings per share. The company’s revenue for the quarter was up 26.5% on a year-over-year basis. On average, equities research analysts anticipate that Vericel Corporation will post 0.78 EPS for the current fiscal year.
Insider Activity
In related news, Director Robert Zerbe sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total transaction of $156,690.00. Following the completion of the transaction, the director owned 32,995 shares of the company’s stock, valued at approximately $1,723,328.85. The trade was a 8.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Siegal sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $52.90, for a total transaction of $79,350.00. Following the sale, the insider directly owned 1,259 shares in the company, valued at $66,601.10. This trade represents a 54.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 49,008 shares of company stock worth $2,701,078 in the last three months. Insiders own 7.60% of the company’s stock.
Vericel Company Profile
Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.
Further Reading
- Five stocks we like better than Vericel
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL – Free Report).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
